Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study

ConclusionsOur data suggest that patients with CM responding to BT-A during the first two cycles will likely benefit from the third cycle of treatment, while the probability that non-responders to the first two cycles start responding during the third cycle is low. These results can help guide the individual decision to stop or continue treatment after the second cycle in patients who have not responded to the first two cycles.

http://link.springer.com/10.1007/s40122-021-00253-0

Source: Pain and Therapy - March 28, 2021 Category: Anesthesiology Source Type: research